Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Trevi Therapeutics (NASDAQ:TRVI) in a report issued on Wednesday,Benzinga reports. The firm currently has a $8.00 price objective on the stock.

TRVI has been the topic of several other reports. Raymond James began coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target on the stock. Leerink Partners initiated coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a report on Tuesday, October 22nd. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $9.13.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI opened at $2.76 on Wednesday. Trevi Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.00. The business has a 50 day moving average of $2.99 and a 200-day moving average of $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the company posted ($0.08) earnings per share. As a group, analysts expect that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

Large investors have recently modified their holdings of the business. Logos Global Management LP lifted its position in shares of Trevi Therapeutics by 27.3% during the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after buying an additional 600,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Trevi Therapeutics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after acquiring an additional 60,249 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in shares of Trevi Therapeutics in the second quarter worth about $4,395,000. Rosalind Advisors Inc. boosted its stake in shares of Trevi Therapeutics by 50.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after purchasing an additional 465,561 shares in the last quarter. Finally, MAI Capital Management grew its holdings in shares of Trevi Therapeutics by 0.7% during the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after purchasing an additional 8,789 shares during the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.